Trial Profile
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases; Breast cancer; Cancer; Cancer metastases; Multiple myeloma; Prostate cancer
- Focus Adverse reactions
- Sponsors Amgen
- 19 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Aug 2009 New trial record